Similarly, five guidelines recommended initiation of SGLT2 inhibitors, typically in patients with type 2 diabetes mellitus (T2DM) and a high risk/presence of CVD.12,13,15,17,19 ESC also recommended initiation of SGLT2 inhibitors and finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), in T2DM with concomitant chronic kidney disease (CKD). Here, NR3C2 is linked to type 2 diabetes mellitus.